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Abstract  Prostate  cancer  is  the  cancer  exhibiting  the  highest  incidence  rate  and  it  appears
as the  second  cause  of  cancer  death  in  men,  after  lung  cancer.  Prostate  cancer  is  difﬁcult
to detect,  and  the  treatment  efﬁcacy  remains  limited  despite  the  increase  use  of  biological
tests (prostate-speciﬁc  antigen  [PSA]  dosage),  the  development  of  new  imaging  modalities,
and the  use  of  invasive  procedures  such  as  biopsy.  Ultrasound  elastography  is  a  novel  imag-
ing technique  capable  of  mapping  tissue  stiffness  of  the  prostate.  It  is  known  that  prostatic
cancer tissue  is  often  harder  than  healthy  tissue  (information  used  by  digital  rectal  examina-
tion [DRE]).  Two  elastography  techniques  have  been  developed  based  on  different  principles:
ﬁrst, quasi-static  (or  strain)  technique,  and  second,  shear  wave  technique.  The  tissue  stiff-
ness information  provided  by  US  elastography  should  improve  the  detection  of  prostate  cancer
and provide  guidance  for  biopsy.  Prostate  elastography  provides  high  sensitivity  for  detecting
prostate  cancer  and  shows  high  negative  predictive  values,  ensuring  that  few  cancers  will  be
missed. US  elastography  should  become  an  additional  method  of  imaging  the  prostate,  comple-
menting the  conventional  transrectal  ultrasound  and  MRI.  This  technique  requires  signiﬁcant
training  (especially  for  quasi-static  elastography)  to  become  familiar  with  acquisition  process,
acquisition  technique,  characteristics  and  limitations,  and  to  achieve  correct  diagnoses.
© 2013  Éditions  françaises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.Prostate  cancer  is  a public  health  issue,  because  it  is  the  cancer  with  the  highest  incidence
rate  and  the  second  cause  of  cancer  death  in  men,  the  ﬁrst  cause  being  lung  cancer.  There
were  around  790,000  cases  in  the  United  States  in  2012,  and  241,740  new  cases  [1].  These
ﬁgures  are  slightly  higher  than  those  for  breast  cancer  for  the  same  year.  In  France,  the
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umber  of  new  cases  is  estimated  to  be  71,000  in  2011
ith  a  signiﬁcant  increasing  rate  (+  8.5%  every  year  between
000  and  2005).  This  is  as  a  result  of  combined  ageing  of
he  population,  improvement  in  diagnostic  techniques  and
ncreased  use  of  prostatic  speciﬁc  antigen  (PSA)  dosage
2].  The  number  of  new  cases  is  around  3.3  times  higher
han  that  of  colorectal  cancer,  while  the  number  of  deaths
elated  to  prostate  cancer  is  estimated  to  be  8700  in  2011,
lmost  identical  to  that  of  colorectal  cancer  (9200  deaths).
espite  improvement  in  diagnosis  due  to  imaging  techniques
rogress  and  better  treatment  efﬁcacy,  the  speciﬁc  mortal-
ty  rate  is  only  falling  slightly,  but  this  fall  is  constant  (−2.5%
er  year  for  the  period  2000—2005).  There  is  no  systematic
creening.  Individual  screening  relies  on  annual  digital  rectal
xamination  (DRE)  and  PSA  dosage.  Detection  and  charac-
erization  of  prostate  nodules  using  ultrasound  or  MRI  remain
ifﬁcult  to  carry  out  [3].
rostate cancer screening
rostate  cancer  systematic  screening  is  challenged  again
ollowing  the  publication  of  recent  recommendations  by
he  French  National  Authority  for  Health  (HAS)  [2].
he  aim  of  systematic  screening  is  to  detect  a clin-
cally  signiﬁcant  cancer  in  healthy  men  to  identify
 curable  lesion  at  an  early  stage,  thereby  improv-
ng  the  prognosis  of  the  disease.  Its  beneﬁts  must  be
reater  than  its  drawbacks,  which  include  complications
elated  to  treatment  (urinary  incontinence,  impotence,
adiation  cystitis  or  proctitis),  to  diagnostic  methods
hematuria/rectorrhagia/retention/post-biopsy  prostatitis,
omplications  due  to  MRI  and  administration  of  contrast
gents,  PSA  false  positives),  to  diagnostic  psychological
mpact  and  ﬁnally  to  false  positives  of  MRI  examinations
r  PSA  dosage.  The  limits  of  screening  stem  from  the  lack
f  an  effective  and  simple  test  to  pinpoint  men  with  a  risk
f  cancer  high  enough  to  justify  continuing  the  diagnostic
rocedure  with  more  aggressive  tests.  Screening  may  con-
ern  either  an  entire  population  based  on  age  (systematic
creening),  or  a  target  population  considered  to  be  at  high
isk.  Screening  is  considered  to  be  organized  when  it  con-
erns  an  entire  population  actively  recruited,  or  individual
hen  the  population  is  recruited  when  treatment  is  sought.
n  France,  just  like  in  the  United  States  or  in  United  King-
om,  there  is  no  systematic  screening,  because  of  the  lack
f  proof  that  speciﬁc  death  rate  can  be  reduced  [2].  We
annot,  however,  rule  out  the  role  played  by  extending  indi-
idual  screening  through  combining  PSA  dosage  to  DRE  in  the
ecent  fall  in  speciﬁc  death  rate.
However,  individual  screening  for  prostate  cancer  may
e  offered  to  men  over  50  without  a  predisposition,
fter  disclosing  the  beneﬁts  and  risks  to  the  patient.
or  high-risk  patients  (ﬁrst  degree  family  history,  Afro-
merican  patients),  screening  may  even  start  earlier,  at
ge  40.
Individual  screening  for  prostate  cancer  is  based  on  DRE
nd  PSA  dosage.  However,  increase  of  PSA  is  not  speciﬁc  of
rostate  cancer  and  can  be  related  to  prostatic  hyperplasia,
cute  and  chronic  prostatitis,  or  prostate  trauma  (caused
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igniﬁcant  prostate  cancers  with  PSA  levels  lower  than  the
hreshold  of  4  ng/ml.
rostate cancer diagnosis
rostate  cancer  may  be  suspected  if  PSA  level  is  abnormal
r  increasing,  or  if  DRE  is  abnormal.  Further  tests  are  then
arried  out,  which  in  most  cases  mean  an  ultrasound-guided
ransrectal  biopsy.  Prostate  biopsy  also  allows  estimating  the
umor  volume  (number  and  spatial  dispersion  of  the  positive
ores,  length  of  the  tumor  in  each  positive  sample)  and  its
ggressiveness  (Gleason  score,  invasion  of  the  capsule  or  the
eurovascular  bundles)  [4].
However,  this  approach  has  several  limitations.  PSA
creening  leads  to  a  substantial  number  of  unnecessary  biop-
ies  in  patients  with  no  cancer  or  with  indolent  cancer  that
o  not  need  immediate  treatment,  with  an  estimated  over-
etection  rate  ranging  from  27  to  56%  [4].  The  false  negative
ate  of  prostate  biopsy  varies  from  17  to  21%,  in  patients
ith  a  negative  ﬁrst  series  of  biopsies  [5,6].  Many  urologists
re  now  facing  a  dilemma  when  patients  present  with  an
bnormal  level  of  PSA  and  negative  biopsies:  when  should
ne  stop  and  when  should  one  continue  carrying  out  biop-
ies  [7]?  Finally,  although  PSA  levels  and  biopsy  results  are
orrelated  with  the  clinical  stage,  tumour  volume  and  histo-
ogic  tumour  grade,  the  information  provided  is  limited  for
redicting  the  tumour  mass  and  its  aggressiveness  in  each
atient.
The  increase  in  the  number  of  core  biopsies  (saturation
iopsies  up  to  40)  improves  PC  detection  and  offers  a  better
stimation  of  the  tumor  volume  and  Gleason  score  [8,9],  but
as  many  limitations  including  increased  cost  and  morbidity,
nd  over  diagnosis  and  overtreatment  of  microscopic  tumor
oci  [10,11]; saturation  biopsies  cannot  really  rule  out  PC
8,9].
MRI  recently  provided  interesting  results  in  terms  of
etecting  and  locating  tumors  [11—15]. Multi-parametric
RI  (MP-MRI),  combining  T2-weighted  imaging  and  func-
ional  sequences  has  become  a  major  modality  for  tumor
etection  and  staging  [11—15],  particularly  in  candidates  to
adical  prostatectomy,  with  areas  under  the  ROC  curve  over
.9  [16—19].  However,  MRI  performance  varies  depending
n  which  combination  of  positive  features  is  selected  for
ancer  diagnosis  between  T2-weighted  sequence,  diffusion
equence  (including  ADC  calculation),  dynamic  contrast-
nhanced  sequence  and  sometimes  spectro-MRI  [20,21].  If
he  sensitivity  of  MP-MRI  is  high,  its  speciﬁcity  remains  low
specially  because  it  is  affected  by  the  increased  vascular-
ty  of  the  normal  inner  gland  and  coexisting  benign  prostate
yperplasic  nodules.  Also  while  its  sensitivity  is  high  for  large
nd  high  Gleason  grade  prostate  cancers,  its  remains  low
or  the  detection  of  small  lesions  of  limited  Gleason  score
≤  6)  [22]  and  there  is  little  information  to  help  distinguish
etween  aggressive  and  indolent  tumors  [23].  Quantita-
ive  approaches,  in  particular  with  diffusion  and  dynamic
ontrast-enhanced  sequences,  could  probably  help  to  stan-
ardize  the  interpretation  of  images  and  to  deﬁne  thresholds
or  distinguishing  aggressive  tumors  [24]. In  addition,  it  is
ifﬁcult  to  decide  on  the  best  way  to  combine  the  results
f  these  various  approaches,  especially  when  they  are  dis-
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reproducibility  in  the  interpretation  of  MP-MRI  data  from
one  radiologist  to  another.
Conventional  TRUS  B-mode  imaging  has  limited  sensitiv-
ity  and  speciﬁcity  in  between  40  to  50%  for  PC  detection,
and  is  not  signiﬁcantly  improved  by  the  use  of  Colour/Power
Doppler  [26—28].  Contrast-Enhanced  Ultrasound  is  still
under  evaluation  and  can  sensitize  prostate  biopsy  [29—31].
Prostate  cancer  is  a  stiff  lesion,  and  this  feature  plays
a  major  role  during  DRE  [32,33].  A  technique  able  to  map
tissue  elasticity  would  therefore  be  useful  in  detecting  and
locating  cancer  areas  within  the  prostate.  Two  ultrasound
elastography  techniques  have  been  developed,  based  on
different  approaches:  the  ﬁrst  one  entails  the  use  of  the
quasi-static  method,  and  the  second  uses  the  transient  shear
wave  technique  [34].
In  this  article,  we  present  a  review  of  these  two  tech-
niques,  describing  the  following  points:
• how  these  techniques  are  applied  in  the  framework  of
prostate  cancer;
• interpretations  of  elastography  results;
• performance  of  these  two  techniques  for  the  detection
and  characterisation  of  prostate  cancers;
• practical  advices  for  using  these  techniques  in  the  clinical
environment;
• and  ﬁnally  their  limitations.
Quasi-static elastography
Method
Soft  tissues  tend  to  exhibit  higher  strain  (deformation)
than  stiffer  areas  when  compression  is  applied.  Quasi-static
ultrasound  elastography  (or  strain  elastography)  of  the
prostate  is  based  on  the  analysis  of  tissue  deformation
in  a  region,  generated  by  inducing  a  mechanical  stress





Figure 1. The transrectal transducer is used as a compression device
comparison, before and after the compression, allows calculation of loca
colour map called an elastogram.553
tself);  the  deformation  is  then  supposed  to  be  uniform  in
pace  and  intensity  [35—40].  A  water-ﬁlled  balloon  may  be
laced  between  the  probe  and  the  rectal  wall  to  improve
he  homogeneity  of  the  deformation  [41].  A  speckle  com-
arison,  before  and  after  compression,  yields  to  a  colour
ap  of  local  tissue  deformation  or  strain  called  elastogram.
issue  stiffness  is  estimated  by  visualizing  the  differences  in
train  between  adjacent  regions.  Therefore,  no  quantitative
lasticity  analysis  is  available.  The  stiffness  colour  scale  is
utomatically  distributed  from  the  lowest  to  the  highest
train  found  in  the  image  plane,  and  this  is  why  the  size  and
osition  of  the  stiffness  box  may  induce  some  variability.
he  ROI  should  cover  the  entire  prostate  gland  and  the
urrounding  tissues.  Semi-quantitative  information  can  be
erived  by  measuring  strain  ratio  between  two  ROI  (usually
ne  considered  ‘‘normal’’  and  the  other  ‘‘abnormal’’).  The
train  for  each  pixel  is  colour  coded  (or  grey  scale  coded)
nd  displayed  as  overlay  on  the  B-mode  image  (Fig.  1).
nterpretation
uasi-static  elastography  requires  slight  compressions  and
ecompressions,  which  are  induced  by  the  transrectal
robe.  A  quality  index  may  help  in  ensuring  appropriate
peed  and  pressure.  Stiff  tissues  exhibit  a  reduced  strain,
hile  soft  tissues  have  an  increased  strain.  Hypoechoic  hard
esions  are  highly  suspicious  for  malignancy  (Fig.  2).
hear wave elastography (SWE)
ethodnlike  quasi-static  elastography,  SWE  requires  no  compres-
ion  on  the  rectal  wall  to  produce  elastograms.  SWE  is
ased  on  the  measurement  of  shear  wave  velocity  propa-
ating  through  the  tissues  [42].  This  technique  provides  a
 and applies cycles of compression and decompression. A speckle
l tissue deformations and display/code them as a two-dimensional
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Figure 2. Patient with a PSA of 22 ng/mL, quasi-static elastography of the prostate. The cancer shows little deformation and is shown coded
as blue-violet (showing the hard tissue in this system). The lesion is likely to invade the prostate capsule and extend to the peri-prostatic



























































tuantitative  map  of  soft  tissues  elastic  properties  in  real
ime,  displayed  either  in  kilopascal  or  in  meter  per  second.
WE  basic  principle  relies  on  two  successive  steps:  ﬁrst,  a
hear  wave  is  remotely  induced  by  the  endorectal  trans-
ucer  in  the  prostate,  using  the  acoustic  radiation  force
f  a  focused  ultrasonic  beam,  and  second,  the  shear  wave
ropagation  is  captured  by  imaging  the  prostate.  The  shear
odulus  (i.e.  stiffness)  is  derived  by  measuring  the  shear
ave  propagation  velocity  (c.f.  J.L.  Gennisson  article).  The
hear  wave  speed  (in  meter  per  second)  or  the  Young’s  modu-
us  (in  kilopascal)  is  color-coded  for  each  pixel  and  displayed
s  an  overlay  on  the  image  in  B-mode  (Fig.  3).
nterpretation
ptimized  settings  include  maximizing  penetration  and  set-
ing  up  an  appropriate  scale  (70  to  90  kPa).  The  ROI  can  only
over  half  of  the  gland  in  a  transverse  plane,  so  each  side  of
he  prostate  is  scanned  separately  and  stored  digitally  from
ase  to  apex  for  further  review  and  stiffness  measurements.
or  each  plane,  the  transducer  is  maintained  in  a  steady-
tate  position  during  2  to  4  seconds  until  stabilization  of  the
ignals.  Stiff  tissues  are  colour-coded  in  red,  while  soft  tis-
ues  appear  in  blue.  Hypoechoic  stiff  lesions  are  suspicious
or  malignancy.  The  elasticity  values  (mean,  standard  devi-
tion,  min  and  max)  are  then  calculated  for  each  ROI.  The
atio  between  the  mean  values  of  two  ROIs  placed  in  a  sus-
icious  region  and  in  the  adjacent  normal  peripheral  zone
an  be  calculated.
In  young  patients  without  prostate  disease,  the  entire
rostate  exhibits  a  similar  soft  appearance  with  elasticity
alues  below  30  kPa  (Fig.  3).  In  benign  prostate  hypertrophy,
he  peripheral  zone  remains  soft  and  homogeneous,  while
he  central  and  transition  zones  become  heterogeneous  and
ard,  with  increased  values  (particularly  in  the  presence  of




sodules  are  soft  (<  35  kPa),  while  cancer  nodules  are  stiffer
>  35  kPa).
erformance of elastography in detecting
nd characterizing prostate cancer
everal  studies  point  evidence  that  elastography  provides
seful  additional  information  to  conventional  TRUS  for  PCA
etection.  Three  different  applications  have  been  identi-
ed:  ﬁrstly,  characterization  of  abnormal  regions  detected
y  B-mode  imaging,  colour  Doppler  US  or  MRI;  secondly,
etection  of  lesions  not  seen  with  any  imaging  technique;
nd  thirdly,  biopsy  targeting.  SWE  allows  continuous  scan-
ing  of  the  prostate  from  base  to  apex  to  detect  stiff  regions,
nd  provide  quantitative  elasticity  values  of  nodules  and
tiffness  ratio  between  nodules  and  adjacent  prostate  tis-
ue.
Most  studies  report  a  signiﬁcant  improvement  in  prostate
ancer  identiﬁcation  with  quasi-static  elastography,  includ-
ng  guidance  for  targeted  biopsies  [36,37,39,40,43].
owever,  there  are  still  some  controversies  and  some
ecent  studies  reported  an  inability  to  differentiate  prostate
ancer  from  chronic  prostatitis  [44]  or  that  quasi-static  elas-
ography  was  less  accurate  than  randomized  biopsies  for
dentifying  prostate  cancer  (Fig.  5)  [45].  Improvement  in
iopsy  guidance  is  often  reported  in  the  literature  [46—48],
ut  some  well-designed  studies  did  not  conﬁrm  such  results
45,49].
SWE  is  a  more  recent  technique  and  there  are  few  reports
o  date.  The  best  stiffness  cut-off  value  to  differentiate
enign  from  malignant  lesions  was  found  to  be  35  and  37  kPa
n  two  independent  studies  [50,51].  In  both  of  these  stud-
es,  the  lowest  performance  for  SWE  in  terms  of  sensitivity,
peciﬁcity,  positive  and  negative  predictive  values  were  63,
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Figure 3. A 32-year-old man, infertility, presenting with early benign prostate hypertrophy. Shear wave elastography with sections from
the base to the apex (a, b, c, d) shows a very homogeneous and very soft peripheral zone, coded in blue, with mean elastography values
below 10 kPa (the elasticity scale varies from 0 to 70 kPa). The central and transitional zones are already heterogeneous and contain nodules
with increased hardness.
556  
Figure 4. A 58-year-old man with a PSA of 4.6 ng/mL. A large
calciﬁcation, clearly visible on B-mode imaging in the right mid-

















































iannot be confused with a parenchymal nodule, and it is not a SWE
alse positive.
1,  69,4  and  91%,  respectively  (Fig.  6).  The  shear  wave
lasticity  ratio  performed  better,  presumably  because  it
akes  into  account  the  increased  stiffness  of  the  peripheral
one  from  calciﬁcations  and  chronic  prostatitis.  The  ratios
etween  the  nodule  and  the  adjacent  peripheral  gland  tissue
or  benign  and  malignant  lesions  were  1.5  ±  0.9  and  4.0  ±  1.9
p  < 0,002),  respectively  [50].
Prostate  elastography  may  be  recommended  to  increase
iagnostic  conﬁdence  in  the  detection  of  prostate  cancer
characterization  of  a  focal  abnormal  area,  detection  of  a
tiff  region  not  seen  with  other  imaging  techniques)  and  to
ncrease  the  positive  predictive  biopsy  rate.
ractical advice for carrying out prostate
lastography
o  speciﬁc  preparation  is  required  for  either  quasi-static  or
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maging  is  conducted  after  a  complete,  high  quality  TRUS
xamination  in  the  transverse  and  sagittal  planes,  in  order
o  measure  prostate  volume,  identify  suspicious  areas  in
he  peripheral  gland  and  analyse  the  peri-prostatic  space
including  the  seminal  vesicles).
Prostate  elastography  is  recommended  only  if  the  user
as  adequate  training  and  experience  with  the  system  and
he  ultrasound  elastography  technique  used.  He  should  also
e  familiar  to  prostate  TRUS  and  US  guided  biopsies.
No  study  has  compared  the  quasi-static  and  SWE  tech-
iques.  SWE  does,  however,  appear  easier  to  carry  out  and
equires  less  training,  because  no  manual  compression  is
equired,  and  because  this  method  is  less  subject  to  oper-
tor  variability.  However,  experience  and  knowledge  of  the
imitations  of  both  techniques  are  essential  for  both  meth-
ds.
imitations and artifacts
oth  elastography  techniques  have  limitations.  For  the
uasi-static  technique,  they  include  the  lack  of  uni-
orm  compression  over  the  entire  gland,  the  intra  and
nter-operator  dependency,  the  penetration  issues  in  large
rostate  glands,  the  level  of  training,  and  the  artefacts  due
o  slippage  of  the  compression  plane  that  can  occur  in  up  to
2%  of  the  images  [43]. This  artifact  is  reduced  with  training
nd  balloon  interposition.
SWE  also  has  a number  of  limitations  including  the
inimal  pressure  applied  to  the  transducer  (an  end-ﬁre
ransducer  requires  bending  to  image  the  prostate),  the
low  frame  rate  (one  image  per  second),  the  limited  size
f  the  ROI  (only  half  of  the  prostate  gland  is  covered)
Figs.  3,  4,  6  and  7),  to  the  delay  to  achieve  image  stabiliza-
ion  for  each  plane  acquisition  and  the  signal  attenuation  in
arge  prostates  making  the  evaluation  of  the  anterior  tran-
itional  zone  difﬁcult  or  impossible  (Fig.  7).
Both  techniques  are  also  subject  to  the  same  intrinsic  lim-
tations:  not  all  cancers  are  stiff,  and  all  stiff  lesions  are  not
ancerous  (calciﬁcations,  ﬁbrosis.  . .). Elasticity  information
ust  always  be  combined  with  the  results  of  the  transrectal
S  B-mode,  and  with  the  results  of  other  imaging  techniques
uch  as  MRI.
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Figure 5. A 65-year-old patient, with an increasing and high PSA at 12 ng/mL. The ﬁrst series of biopsies was carried out 18 months
earlier and revealed a 2 mm micro-focus of cancer Gleason 6. The patient was placed under active surveillance. In B-mode (a) and colour
Doppler US (b), there was no focal abnormality and particularly no peripheral hypoechogenic area with increased vascularity. Quasi-static
elastography was difﬁcult to interpret in the absence of focal increased stiffness area; only some small poorly delineated stiff areas were
seen without B-mode abnormal changes. All 15 samples (systematic posterior and anterior biopsies) came back positive with tumour lengths
of 11 to 21 mm and a Gleason score of 7.
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Figure 6. A 57-year-old man with PSA values of 6.6 ng/mL and abnormal rectal examination results, this is the second series of prostate
biopsies. A focal nodule was detected at TRUS as hypoechogenic and hypervascular, as well as at MP-MRI (T2, DCE and diffusion) at the
anterior right base (a). SWE showed an increased stiffness (mean value of 87 kPa) (b), while in comparison the left side of the prostate
exhibited normal stiffness values (c). The three samples taken in stiff focal lesion revealed an adenocarcinoma Gleason 6 measuring 7 mm.
Another peripheral nodule located in the right paramedian base was detected only with SWE, as it was isoechoic to normal prostate
parenchyma. This lesion was not seen at MP-MRI. This stiff lesion exhibit
was also biopsied, revealing another Gleason 7 cancer, measuring 11 mm
Figure 7. A 53-year-old man with PSA values of 5.5 ng/mL and
a prostate volume of 88 mL. As the prostate was very large, shear





















sible  with  shear  wave  techniques,  and  volumetric  fusionland because this region was too far away from the transducer
attenuation effect).onclusion
ltrasound  elastography  brings  in  a  new  parameter  —  tissue
tiffness  —  which  provides  additional  information  for
w
n
bed high elasticity value of 54 kPa and a ratio of 1.8 (d). This nodule
 (longer than the lesion seen at MP-MRI and B-mode TRUS.
etecting  prostate  cancer  and  guiding  biopsies.  Elastog-
aphy  provides  greater  sensitivity  for  detecting  prostate
ancer  and  exhibits  a  high  negative  predictive  value,
nsuring  that  few  cancers  are  missed  in  the  peripheral  zone
f  the  prostate.  Elastography  should  become  an  additional
ethod  of  examination  of  the  prostate  to  complement
raditional  transrectal  ultrasound  imaging  and  MRI,  and
his  method  could  eventually  become  as  routinely  used
s  colour  Doppler.  However,  this  technique  does  require
 learning  curve  (mainly  for  quasi-static  technique  as  the
perator  is  the  one  inducing  tissue  deformation  by  applying
lternative  pushes  with  the  transducer),  so  that  the  user
ecomes  familiar  with  the  characteristics  and  limitations  of
he  technique  used,  in  order  to  produce  a  correct  diagnosis.
In  the  future,  elastography  should  include  volumetric
lastography  of  the  prostate  (3D),  which  will  only  be  pos-ith  other  imaging  methods  such  as  MRI.  These  new  tech-
iques  should  improve  guiding  capabilities  in  order  to  target













[Ultrasound  elastography  of  the  prostate:  State  of  the  art  
of  prostate  cancer  and  assessment  of  its  aggressiveness
remain  essential  for  developing  focal  treatment  to  improve
patients’  quality  of  life.
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